Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas

American Journal of Clinical Pathology

Volumn 109, Issue 2, 1998, Pages 163-168

  Scalzo, David A ^a   Kallakury, Bhaskar V S ^a   Gaddipati, Ramakrishna V ^a   Sheehan, Christine E ^a   Keys, Henry M ^a   Savage, Duncan ^a   Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Adenocarcinoma; HER 2 neu; MIB 1; Prognosis; Proliferation; Prostate; Radiation

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL PROLIFERATION; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CARCINOMA;

EID: 0031931112     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/109.2.163     Document Type: Article

References (37)

1. Boring CC, Squires TS, Tong T. Cancer statistics. Cancer. 1994;44:7-26.
2. Bagshaw MA, Ray GR, Pistenma PA, et al. External beam radiation therapy of primary carcinoma of the prostate. Cancer. 1975;36:723-728.
3. Gibbons, RP, Mason JT, Correa RJ Jr, et al. Carcinoma of the prostate: local control with external beam radiation therapy. J Urol. 1979;121:310-312.
4. Bagshaw MA. Potential for radiotherapy alone in prostatic cancer. Cancer. 1985;55:2079-2085.
5. Zagars GK, Von Eschenbach AC, Johnson DE, et al. Stage C adenocarcinoma of the prostate: an analysis of 4551 patients treated with external beam radiation. Cancer. 1987;60:1489-1499.
6. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer of 5 years after external beam radiation. J Urol. 1995;154:456-459.
7. Swanson GP, Cupps RE, Utz DC, et al. Definitive therapy for prostate carcinoma: Mayo Clinic results of 15 years after treatment. Br J Radiol. 1994;67:877-899.
8. Hanks GE, Diamond JJ, Krall JM, et al. A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States. Int J Radiat Oncol Biol Phys. 1987;13:499-505.
9. Schellhammer PF, El-Mahdi AM, Wright GL, et al. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology. 1993;42:13-20.
10. Kaplan ID, Cox RS, Bagshaw MA. Prostate specific antigen after external beam radiotherapy for prostatic cancer: follow-up. J Urol. 1993;149:519-522.
11. Zagars GK, Von Eschenback AC. Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer. 1993;72:538-548.
12. Goad JR, Chang SJ, Ohori M, et al. PSA after definitive radiotherapy for clinically localized prostate cancer. Urol Clin North Am. 1993;20:727-736.
13. Zagars GK. Serum PSA as a tumor marker for patients undergoing definitive radiation therapy. Urol Clin North Am. 1993;20:737-747.
14. Lipsett JA, Cosgrove MD, Green N, et al. Factors influencing prognosis in the radiotherapeutic management of carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1976;1:1049-1058.
15. Hanks GE, Leibel SA, Krall JM, et al. Patterns of care studies: Dose-response observations for local control of adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1985;11:153-157.
16. Hanks GE, Martz, KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys. 1988;15:1299-1305.
17. Ross JS, Sheehan C, Hayner-Buchan AM, et al. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol. 1997;28:827-833.
18. Ross JS, Sheehan CE, Hayner-Buchan AM, et al. Prognostic significance of HER-2/neu gene amplification status by fluorescence in-situ hybridization in prostatic cancer. Cancer. 1997;79:2162-2170.
19. Bubendorf L, Sauter G, Moch H, et al. Ki-67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol. 1996;178:437-441.
20. Crook J, Robertson S, Esche B. Proliferative cell nuclear antigen in post-radiotherapy prostate biopsies. Int J Radiat Oncol Biol Phys. 1994;30:303-308.
21. Gleason D. Histologic grading and clinical staging of carcinoma of the prostate. In: Tannenbaum M, ed. Urologic Pathology: The Prostate. Philadelphia, Pa: Lea & Febiger; 1977:171-198.
22. Gleason DF, Mellinger GT. Veterans Administration Cooperative Urological Research Group 1974. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol. 1974;111:58-64.
23. Gittes, RF. Carcinoma of the prostate. N Engl J Med. 1991;324:236.
24. Nachtsheim D, McAninch J, Stutzman R, et al. Latent residual tumor following external radiotherapy for prostate adenocarcinoma. J Urol. 1978;120:312-314.
25. Scardino P, Wheele T. Prostatic biopsy after irradiation therapy for prostate cancer. Urology. 1985;25:39-16.
26. Ross JS, Figge H, Bui HX, et al. Prediction of pathologic stage and post prostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer. 1994;74:2811-2818.
27. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13-20.
28. Gerdes J. Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715.
29. Hall PA, Woods AL. Immunohistochemical markers of cellular proliferation: achievements, problems and prospects. Cell Tissue Kinet. 1990;23:505-522.
30. Raymond WA, Leong AS, Bolt JW, et al. Growth fractions in human prostatic carcinoma determined by Ki-67 immunostaining. J Pathol. 1988;156:161-167.
31. Galle MP, Visser-De Jong E, Ten Kate FJ, et al. Monoclonal Antibody Ki-67 defined growth fraction in benign prostatic hyperplasia and prostatic cancer J Urol. 1989;142:1342-1346.
32. Thompson SJ, Mellon K, Charlton RG, et al. p53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol. 1992;69:609-613.
33. McLoughlin J, Foster CS, Price P, et al. Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Br J Urol. 1993;72:92-97.
34. Centeno BA, Zietman AL, Shipley WU, et al. Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 1994;30:309-315.
35. Visakorpi T, Kallioniemi OP, Koivula T, et al. Expression of epidermal growth factor receptor and ERBB2 (HER-2/neu) oncoprotein in prostatic carcinomas. Mod Pathol. 1992;5:643-048.
36. Sadasivan R, Morgan R, Jennings S, et al. Overexpression of HER-2/neu may be an indicator of poor prognosis in prostate cancer. J Urol. 1993;150:126-131.
37. Ross JS, Nazeer T, Church K, et al. Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis. Cancer. 1993;72:3020-3028.